Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.65 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | TPMT | P51580 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4585821 | 1.00 | NQO2 (0.65) | NQO2MAOBMEN1GAAKMT2A | |
| SCHEMBL4585814 | 1.00 | NQO2 (0.65) | NQO2MAOBMEN1GAAKMT2A | |
| SCHEMBL14613395 | 0.87 | PDE4A (0.54) | NQO2MAOBGAACYP1A2CYP3A4 | |
| SCHEMBL13293828 | 0.86 | NQO2 (0.51) | NQO2MAOBMEN1GAAKMT2A | |
| SCHEMBL8322998 | 0.86 | PRSS1 (0.52) | NQO2MEN1KMT2ATSHRKDM4E | |
| SCHEMBL3236825 | 0.82 | NPC1 (0.70) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3236841 | 0.82 | NPC1 (0.70) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3236834 | 0.82 | NPC1 (0.70) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL8324910 | 0.82 | NQO2 (0.47) | NQO2MAOBMEN1GAAKMT2A | |
| SCHEMBL5441428 | 0.80 | POLB (0.51) | NQO2TSHRPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9408852-B2 | Method of lowering serum uric acid levels with (S)-tofisopam | PHARMOS CORPORATION (US) | 2016-08-09 | — | — | US | disclosed |
| US-20130045966-A1 | Method of Lowering Serum Uric Acid Levels With (S)-Tofisopam | PHARMOS CORPORATION (US) | 2013-02-21 | — | — | US | disclosed |
| EP-1567162-A4 | TREATMENT OF IRRITABLE BOWEL SYNDROME AND NONULCER DYSPEPSIA WITH SUBSTITUTED 2,3-BENZODIAZEPINES | VELA ACQUISITION CORP (US) | 2008-04-30 | — | — | EP | disclosed |
| US-20070032479-A1 | Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines | VELA ACQUISITION CORPORATION | 2007-02-08 | — | — | US | disclosed |
| US-7022700-B2 | Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines | VELA PHARMACEUTICALS, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| EP-1567162-A2 | TREATMENT OF IRRITABLE BOWEL SYNDROME AND NONULCER DYSPEPSIA WITH SUBSTITUTED 2,3-BENZODIAZEPINES | Vela Pharmaceuticals Inc. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-6864251-B2 | Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines | VELA PHARMACEUTICALS, INC. (US) | 2005-03-08 | — | — | US | disclosed |
| US-20040254173-A1 | Modulation of dopamine responses with substituted (S)-2,3-benzodiazepines | VELA ACQUISITION CORPORATION | 2004-12-16 | — | — | US | disclosed |
| US-20040229866-A1 | Method of lowering body temperature with (S)-2,3-benzodiazepines | VELA PHARMACEUTICALS, INC. | 2004-11-18 | — | — | US | disclosed |
| US-20040224943-A1 | Method of lowering body temperature with (R) - 2,3-benzodiazepines | VELA ACQUISITION CORPORATION | 2004-11-11 | — | — | US | disclosed |
| US-20040162284-A1 | Method of lowering body temperature with (S) tofisopam | VELA ACQUISITION CORPORATION | 2004-08-19 | — | — | US | disclosed |
| US-20040152695-A1 | Pharmaceutical composition of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine and uses thereof | VELA PHARMACEUTICALS, INC. | 2004-08-05 | — | — | US | disclosed |
| US-20040138210-A1 | Method of increasing neutrophil production using 2,3-benzodiazepines | VELA PHARMACEUTICALS, INC. | 2004-07-15 | — | — | US | disclosed |
| US-20040138209-A1 | Treatment of inflammatory disorders with 2,3- benzodiazepines | VELA PHARMACEUTICALS, INC. | 2004-07-15 | — | — | US | disclosed |
| WO-2004050616-A2 | TREATMENT OF IRRITABLE BOWEL SYNDROME AND NONULCER DYSPEPSIA WITH SUBSTITUTED 2,3-BENZODIAZEPINES | VELA PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| US-20040106601-A1 | Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines | VELA ACQUISITION CORPORATION | 2004-06-03 | — | — | US | disclosed |
| US-20040106602-A1 | Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines | VELA ACQUISITION CORPORATION | 2004-06-03 | — | — | US | disclosed |
| US-6638928-B1 | Benzodiazepines administered for irritable bowel syndrome and nonulcer dyspepsia. | VELA PHARMACEUTICALS, INC. | 2003-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138209-A1 | Treatment of inflammatory disorders with 2,3- benzodiazepines | LTB4R2, LTB4R, GABRA4 | NQO2 1655/4885MAOB 502/4885MEN1 4112/4885 |
| US-20040106602-A1 | Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines | LTB4R2, LTB4R, PTGER4 | NQO2 1807/4885MAOB 534/4885MEN1 4227/4885 |
| US-20040229866-A1 | Method of lowering body temperature with (S)-2,3-benzodiazepines | CYP11B2, CYP2S1, CYP1A2 | NQO2 852/4885MAOB 264/4885MEN1 2972/4885 |
| US-20040152695-A1 | Pharmaceutical composition of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine and uses thereof | GABRA4, GABRA2, GABRB2 | NQO2 3724/4885MAOB 173/4885MEN1 3817/4885 |
| US-20040106601-A1 | Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines | OPRL1, OPRD1, GABRR1 | NQO2 700/4885MAOB 578/4885MEN1 4420/4885 |
| US-20040254173-A1 | Modulation of dopamine responses with substituted (S)-2,3-benzodiazepines | DRD2, OPRD1, DRD1 | NQO2 2054/4885MAOB 193/4885MEN1 4311/4885 |
| US-20040224943-A1 | Method of lowering body temperature with (R) - 2,3-benzodiazepines | GABBR1, GABBR2, CYP11B2 | NQO2 893/4885MAOB 355/4885MEN1 2857/4885 |
| US-20070032479-A1 | Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines | GABBR2, GABBR1, GABRB3 | NQO2 1389/4885MAOB 1327/4885MEN1 4138/4885 |
| US-20040138210-A1 | Method of increasing neutrophil production using 2,3-benzodiazepines | GABRR1, GABRA1, GABRA3 | NQO2 624/4885MAOB 812/4885MEN1 4261/4885 |
| US-20130045966-A1 | Method of Lowering Serum Uric Acid Levels With (S)-Tofisopam | ATIC, NPPA, XPNPEP1 | NQO2 983/4885MAOB 877/4885MEN1 2521/4885 |
| US-20040162284-A1 | Method of lowering body temperature with (S) tofisopam | THOP1, SHBG, NPPA | NQO2 831/4885MAOB 852/4885MEN1 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.